Retrospective study links early cranial radiotherapy with improved outcomes in selected EGFR-mutant lung cancer patients

Early cranial stereotactic radiotherapy combined with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer and limited brain metastases, according to a retrospective study presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer. The analysis suggests that the apparent benefit of adding radiotherapy may depend on whether osimertinib produces a complete response within the brain, an association rather than proof that radiotherapy caused the better outcomes.

Researchers reviewed patients with EGFR-mutant non-small cell lung cancer who had brain metastases at baseline and received first-line osimertinib. They compared outcomes among patients who also received early cranial stereotactic radiotherapy with those treated with osimertinib alone. The analysis also examined when radiotherapy was administered and whether patients achieved an intracranial complete response to systemic therapy. Among 255 patients treated with osimertinib alone, 60 patients, or 23.5%, achieved an intracranial complete response.

Patients who did not achieve an intracranial complete response appeared to derive the greatest overall survival benefit from stereotactic radiotherapy, particularly when it was administered in a consolidative approach. In contrast, researchers observed no clear overall survival benefit from radiotherapy among patients who did achieve a complete intracranial response to osimertinib. Compared with osimertinib alone, consolidative stereotactic radiotherapy was associated with improved overall survival, while concurrent stereotactic radiotherapy was not associated with a statistically significant overall survival improvement. These findings support further evaluation of a response-adapted approach in which consolidative cranial radiotherapy is considered for patients with persistent intracranial disease after osimertinib; they do not establish a new clinical standard.

The study reported cumulative incidences of symptomatic radiation necrosis of 9.3% at one year, 24.0% at two years and 28.2% at three years. The retrospective design is an important limitation because differences between treatment groups may have influenced the observed associations, and the analysis cannot determine that adding stereotactic radiotherapy caused the improvements in intracranial control or overall survival. The results therefore provide additional evidence for study rather than definitive guidance for treatment selection. A randomized clinical trial, NCT06020066, is underway to evaluate the clinical value of consolidative stereotactic radiotherapy in this patient population.

Subject of Research: Response-adapted cranial stereotactic radiotherapy in EGFR-mutant non-small cell lung cancer with limited brain metastases

Article Title: Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases

Article References: Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: EGFR-mutant lung cancer, non-small cell lung cancer, brain metastases, stereotactic radiotherapy, osimertinib, intracranial control, overall survival, radiation necrosis, retrospective study, Early, cranial, radiotherapy